Antidepressants, Antipsychotics, and Mood Stabilizers in Pregnancy: What Do We Know and How Should We Treat Pregnant Women with Depression

Birth Defects Research

Volumn 109, Issue 12, 2017, Pages 933-956

  Ornoy, Asher ^a   Weinstein Fudim, Liza ^a   Ergaz, Zivanit ^a  

^a HEBREW UNIVERSITY   (Israel)

Author keywords

anomalies; antipsychotics; development; mood stabilizers; pregnancy; tricyclic antidepressant

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CARBAMAZEPINE; CHLORPROMAZINE; CLOMIPRAMINE; DESIPRAMINE; DOXEPIN; DULOXETINE; FLUPHENAZINE; HALOPERIDOL; IMIPRAMINE; LAMOTRIGINE; LEVETIRACETAM; LITHIUM; MAPROTILINE; MIANSERIN; MIRTAZAPINE; MOOD STABILIZER; NEFAZODONE; NEUROLEPTIC AGENT; NORTRIPTYLINE; PERPHENAZINE; PROTRIPTYLINE; THIORIDAZINE; TOPIRAMATE; TRIFLUOPERAZINE; VALPROIC ACID; ANTICONVULSIVE AGENT; PSYCHOTROPIC AGENT; TRANQUILIZER; TRICYCLIC ANTIDEPRESSANT AGENT;

ANTIDEPRESSANT ACTIVITY; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; CLONUS; CONGENITAL MALFORMATION; CYANOSIS; DEPRESSION; DEVELOPMENTAL DELAY; EBSTEIN ANOMALY; ECHOCARDIOGRAPHY; FEMALE; FETAL ECHOCARDIOGRAPHY; HUMAN; IRRITABILITY; LACTATION; MENTAL DISEASE; MUSCLE HYPERTONIA; MUSCLE SPASM; NEONATAL ADAPTATION DIFFICULTY; NEWBORN DISEASE; OUTCOME ASSESSMENT; PREGNANCY; PREMATURITY; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; TACHYCARDIA; TACHYPNEA; WITHDRAWAL SYNDROME; ANIMAL; BIPOLAR DISORDER; CHEMICALLY INDUCED; CHILD; DISEASE MODEL; INFANT; MALE; NEWBORN; PREGNANCY COMPLICATION; PRENATAL EXPOSURE; PRESCHOOL CHILD;

ANIMALS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CHILD; CHILD, PRESCHOOL; DEPRESSION; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS; PSYCHOTROPIC DRUGS;

EID: 85026874842     PISSN: None     EISSN: 24721727     Source Type: Journal    
DOI: 10.1002/bdr2.1079     Document Type: Review

References (134)

1. Baker GA, Bromley RL, Briggs M, et al. 2015. IQ at 6 years after in utero exposure to antiepileptic drugs: a controlled cohort study. Neurology 84:382–390.
2. Ban L, Gibson JE, West J, et al. 2014. Maternal depression, antidepressant prescriptions, and congenital anomaly risk in offspring: a population-based cohort study. BJOG 121:1471–1481.
3. Barson AJ. 1972. Malformed infant. Br Med J 2(5804):45.
4. Berard A, Zhao JP, Sheehy O. 2017. Antidepressant use during pregnancy and the risk of major congenital malformations in a cohort of depressed pregnant women: an updated analysis of the Quebec Pregnancy Cohort. BMJ Open 7:e013372.
5. Boukhris T, Sheehy O, Mottron L, Berard A. 2016. Antidepressant use during pregnancy and the risk of autism spectrum disorder in children. JAMA Pediatr 170:117–124.
6. Bromley RL, Calderbank R, Cheyne CP, et al. 2016. Cognition in school-age children exposed to levetiracetam, topiramate, or sodium valproate. Neurology 87:1943–1953.
7. Bromley RL, Mawer G, Clayton-Smith J, et al. 2008. Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology 71:1923–1924.
8. Bromley RL, Mawer G, Love J, et al. 2010. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia 51:2058–2065.
9. Bulletins–Obstetrics ACoP. 2008. ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol 111:1001–1020.
10. Campbell E, Kennedy F, Russell A, et al. 2014. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. J Neurol Neurosurg Psychiatry 85:1029–1034.
11. Christianson AL, Chesler N, Kromberg JG. 1994. Fetal valproate syndrome: clinical and neuro-developmental features in two sibling pairs. Dev Med Child Neurol 36:361–369.
12. Cohen LS, Friedman JM, Jefferson JW, et al. 1994. A reevaluation of risk of in utero exposure to lithium. JAMA 271:146–150.
13. Cohen LS, Viguera AC, McInerney KA, et al. 2016. Reproductive safety of second-generation antipsychotics: current data from the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. Am J Psychiatry 173:263–270.
14. Cummings C, Stewart M, Stevenson M, et al. 2011. Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Arch Dis Child 96:643–647.
15. Cunniff C, Sahn D, Johnson K, Jones K. 1988. Pregnancy outcome in women treated with lithium. Thorofare, NJ: Slack Inc. pp. A217–A217.
16. Cunnington M, Tennis P, International Lamotrigine Pregnancy Registry Scientific Advisory Committee. 2005. Lamotrigine and the risk of malformations in pregnancy. Neurology 64:955–960.
17. Cunnington MC, Weil JG, Messenheimer JA, et al. 2011. Final results from 18 years of the International Lamotrigine Pregnancy Registry. Neurology 76:1817–1823.
18. Czeizel A, Racz J. 1990. Evaluation of drug intake during pregnancy in the Hungarian Case-Control Surveillance of Congenital Anomalies. Teratology 42:505–512.
19. Diav-Citrin O, Shechtman S, Arnon J, Ornoy A. 2001. Is carbamazepine teratogenic? A prospective controlled study of 210 pregnancies. Neurology 57:321–324.
20. Diav-Citrin O, Shechtman S, Bar-Oz B, et al. 2008. Pregnancy outcome after in utero exposure to valproate: evidence of dose relationship in teratogenic effect. CNS Drugs 22:325–334.
21. Diav-Citrin O, Shechtman S, Ornoy S, et al. 2005. Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study. J Clin Psychiatry 66:317–322.
22. Diav-Citrin O, Shechtman S, Tahover E, et al. 2014. Pregnancy outcome following in utero exposure to lithium: a prospective, comparative, observational study. Am J Psychiatry 171:785–794.
23. Diav-Citrin O, Shechtman S, Zvi N, et al. 2017. Is it safe to use lamotrigine during pregnancy? A prospective comparative observational study. Birth Defects Res [Epub ahead of print].
24. Dolk H, Wang H, Loane M, et al. 2016. Lamotrigine use in pregnancy and risk of orofacial cleft and other congenital anomalies. Neurology 86:1716–1725.
25. Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, et al. 2008. Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 34:206–222.
26. Edmonds L, Oakley G. 1990. Ebstein's anomaly and maternal lithium exposure during pregnancy. Teratology 41:551–552.
27. Eggermont E. 1973. Withdrawal symptoms in neonates associated with maternal imipramine therapy. Lancet 2:680.
28. Ergaz Z, Weinstein-Fudim L, Ornoy A. 2016. Genetic and non-genetic animal models for autism spectrum disorders (ASD). Reprod Toxicol 64:116–140.
29. Ewing G, Tatarchuk Y, Appleby D, et al. 2015. Placental transfer of antidepressant medications: implications for postnatal adaptation syndrome. Clin Pharmacokinet 54:359–370.
30. Gaily E, Kantola-Sorsa E, Hiilesmaa V, et al. 2004. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology 62:28–32.
31. Gentile S. 2010a. Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr Bull 36:518–544.
32. Gentile S. 2010b. On categorizing gestational, birth, and neonatal complications following late pregnancy exposure to antidepressants: the prenatal antidepressant exposure syndrome. CNS Spectr 15:167–185.
33. Gentile S, Fusco ML. 2017. Neurodevelopmental outcomes in infants exposed in utero to antipsychotics: a systematic review of published data. CNS Spectr 22:273–281.
34. Green JP, Maayani S. 1977. Tricyclic antidepressant drugs block histamine H2 receptor in brain. Nature 269:163–165.
35. Grzeskowiak LE, Morrison JL, Henriksen TB, et al. 2016. Prenatal antidepressant exposure and child behavioural outcomes at 7 years of age: a study within the Danish National Birth Cohort. BJOG 123:1919–1928.
36. Habermann F, Fritzsche J, Fuhlbruck F, et al. 2013. Atypical antipsychotic drugs and pregnancy outcome: a prospective, cohort study. J Clin Psychopharmacol 33:453–462.
37. Harden CL, Meador KJ, Pennell PB, et al. 2009. Management issues for women with epilepsy-focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 50:1237–1246.
38. Hendrickx AG, Nau H, Binkerd P, et al. 1988. Valproic acid developmental toxicity and pharmacokinetics in the rhesus monkey: an interspecies comparison. Teratology 38:329–345.
39. Hernandez-Diaz S, Smith CR, Shen A, et al. 2012. Comparative safety of antiepileptic drugs during pregnancy. Neurology 78:1692–1699.
40. Holmes LB, Baldwin EJ, Smith CR, et al. 2008. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology 70(Pt 2):2152–2158.
41. Hunt S, Craig J, Russell A, et al. 2006. Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology 67:1876–1879.
42. Hunt S, Russell A, Smithson WH, et al. 2008. Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology 71:272–276.
43. Huybrechts KF, Hernandez-Diaz S, Patorno E, et al. 2016. Antipsychotic use in pregnancy and the risk for congenital malformations. JAMA Psychiatry 73:938–946.
44. Jackson A, Bromley R, Morrow J, et al. 2016. In utero exposure to valproate increases the risk of isolated cleft palate. Arch Dis Child Fetal Neonatal Ed 101:F207–F211.
45. Jacobson SJ, Jones K, Johnson K, et al. 1992. Prospective multicentre study of pregnancy outcome after lithium exposure during first trimester. Lancet 339:530–533.
46. Johnson KC, LaPrairie JL, Brennan PA, et al. 2012. Prenatal antipsychotic exposure and neuromotor performance during infancy. Arch Gen Psychiatry 69:787–794.
47. Jones KL, Lacro RV, Johnson KA, Adams J. 1989. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med 320:1661–1666.
48. Kallen B, Tandberg A. 1983. Lithium and pregnancy. A cohort study on manic-depressive women. Acta Psychiatr Scand 68:134–139.
49. Kaneko S, Battino D, Andermann E, et al. 1999. Congenital malformations due to antiepileptic drugs. Epilepsy Res 33:145–158.
50. Kulkarni J, Storch A, Baraniuk A, et al. 2015. Antipsychotic use in pregnancy. Expert Opin Pharmacother 16:1335–1345.
51. Lennestal R, Kallen B. 2007. Delivery outcome in relation to maternal use of some recently introduced antidepressants. J Clin Psychopharmacol 27:607–613.
52. Liemburg EJ, Knegtering H, Klein HC, et al. 2012. Antipsychotic medication and prefrontal cortex activation: a review of neuroimaging findings. Eur Neuropsychopharmacol 22:387–400.
53. Lupattelli A, Spigset O, Bjornsdottir I, et al. 2015. Patterns and factors associated with low adherence to psychotropic medications during pregnancy–a cross-sectional, multinational web-based study. Depress Anxiety 32:426–436.
54. Margulis AV, Mitchell AA, Gilboa SM, et al. 2012. Use of topiramate in pregnancy and risk of oral clefts. Am J Obstet Gynecol 207:405 e401–407.
55. Massa V, Cabrera RM, Menegola E, et al. 2005. Valproic acid-induced skeletal malformations: associated gene expression cascades. Pharmacogenet Genomics 15:787–800.
56. Matalon S, Schechtman S, Goldzweig G, Ornoy A. 2002. The teratogenic effect of carbamazepine: a meta-analysis of 1255 exposures. Reprod Toxicol 16:9–17.
57. Mawhinney E, Craig J, Morrow J, et al. 2013. Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology 80:400–405.
58. McBride WG. 1972. Limb deformities associated with iminodibenzyl hydrochloride. Med J Aust 1:492.
59. McElhatton PR, Garbis HM, Elefant E, et al. 1996. The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants. A collaborative study of the European Network of Teratology Information Services (ENTIS). Reprod Toxicol 10:285–294.
60. McKenna K, Koren G, Tetelbaum M, et al. 2005. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry 66:444–449; quiz 546.
61. Meador KJ, Baker G, Cohen MJ, et al. 2007. Cognitive/behavioral teratogenetic effects of antiepileptic drugs. Epilepsy Behav 11:292–302.
62. Meador KJ, Baker GA, Browning N, et al. 2009. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med 360:1597–1605.
63. Meador KJ, Baker GA, Browning N, et al. 2013. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol 12:244–252.
64. Mehta N, Chen K, Powrie RO. 2014. Prescribing for the pregnant patient. Cleve Clin J Med 81:367–372.
65. Misri S, Sivertz K. 1991. Tricyclic drugs in pregnancy and lactation: a preliminary report. Int J Psychiatry Med 21:157–171.
66. Molgaard-Nielsen D, Hviid A. 2011. Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA 305:1996–2002.
67. Moore JA. 1995. An assessment of lithium using the IEHR evaluative process for assessing human developmental and reproductive toxicity of agents. IEHR Expert Scientific Committee. Reprod Toxicol 9:175–210.
68. Moore SJ, Turnpenny P, Quinn A, et al. 2000. A clinical study of 57 children with fetal anticonvulsant syndromes. J Med Genet 37:489–497.
69. Moriarty AJ, Nance MR. 1963. Trifluoperazine and pregnancy. Can Med Assoc J 88:375–376.
70. Morrow J, Russell A, Guthrie E, et al. 2006. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 77:193–198.
71. Mula M, Sander JW. 2007. Negative effects of antiepileptic drugs on mood in patients with epilepsy. Drug Saf 30:555–567.
72. Narotsky MG, Francis EZ, Kavlock RJ. 1994. Developmental toxicity and structure-activity relationships of aliphatic acids, including dose-response assessment of valproic acid in mice and rats. Fundam Appl Toxicol 22:251–265.
73. Nars PW, Girard J. 1977. Lithium carbonate intake during pregnancy leading to large goiter in a premature infant. Am J Dis Child 131:924–925.
74. Nath SP, Miller DA, Muraskas JK. 1996. Severe rhinorrhea and respiratory distress in a neonate exposed to fluphenazine hydrochloride prenatally. Ann Pharmacother 30:35–37.
75. Newport DJ, Calamaras MR, DeVane CL, et al. 2007. Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. Am J Psychiatry 164:1214–1220.
76. Nijenhuis CM, Horst PG, Berg LT, Wilffert B. 2012a. Disturbed development of the enteric nervous system after in utero exposure of selective serotonin re-uptake inhibitors and tricyclic antidepressants. Part 1. Literature review. Br J Clin Pharmacol 73:16–26.
77. Nijenhuis CM, ter Horst PG, van Rein N, et al. 2012b. Disturbed development of the enteric nervous system after in utero exposure of selective serotonin re-uptake inhibitors and tricyclic antidepressants. Part 2. Testing the hypotheses. Br J Clin Pharmacol 73:126–134.
78. Nulman I, Rovet J, Stewart DE, et al. 1997. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 336:258–262.
79. Nulman I, Rovet J, Stewart DE, et al. 2002. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 159:1889–1895.
80. Ohman I, Vitols S, Luef G, et al. 2002. Topiramate kinetics during delivery, lactation, and in the neonate: preliminary observations. Epilepsia 43:1157–1160.
81. Omtzigt JG, Los FJ, Grobbee DE, et al. 1992. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology 42(Suppl 5):119–125.
82. Ornoy A. 2009. Valproic acid in pregnancy: how much are we endangering the embryo and fetus? Reprod Toxicol 28:1–10.
83. Ornoy A, Cohen E. 1996. Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Arch Dis Child 75:517–520.
84. Ornoy A, Zvi N, Arnon J, et al. 2008. The outcome of pregnancy following topiramate treatment: a study on 52 pregnancies. Reprod Toxicol 25:388–389.
85. Park JM, Sridaromont S, Ledbetter EO, Terry WM. 1980. Ebstein's anomaly of the tricuspid valve associated with prenatal exposure to lithium carbonate. Am J Dis Child 134:703–704.
86. Peng M, Gao K, Ding Y, et al. 2013. Effects of prenatal exposure to atypical antipsychotics on postnatal development and growth of infants: a case-controlled, prospective study. Psychopharmacology (Berl) 228:577–584.
87. Petersen I, McCrea RL, Sammon CJ, et al. 2016. Risks and benefits of psychotropic medication in pregnancy: cohort studies based on UK electronic primary care health records. Health Technol Assess 20:1–176.
88. Prakash C, Hatters-Friedman S, Moller-Olsen C, North A. 2016. Maternal and fetal outcomes after lamotrigine use in pregnancy: a retrospective analysis from an urban maternal mental health centre in New Zealand. Psychopharmacol Bull 46:63–69.
89. Rahi M, Heikkinen T, Hartter S, et al. 2007. Placental transfer of quetiapine in relation to P-glycoprotein activity. J Psychopharmacol 21:751–756.
90. Rai D, Lee BK, Dalman C, et al. 2013. Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based case-control study. BMJ 346:f2059.
91. Rao JS, Lee HJ, Rapoport SI, Bazinet RP. 2008. Mode of action of mood stabilizers: is the arachidonic acid cascade a common target? Molecular psychiatry 13:585–596.
92. Rasalam AD, Hailey H, Williams JH, et al. 2005. Characteristics of fetal anticonvulsant syndrome associated autistic disorder. Dev Med Child Neurol 47:551–555.
93. Reis M, Kallen B. 2010. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 40:1723–1733.
94. Rihtman T, Parush S, Ornoy A. 2012. Preliminary findings of the developmental effects of in utero exposure to topiramate. Reprod Toxicol 34:308–311.
95. Rihtman T, Parush S, Ornoy A. 2013. Developmental outcomes at preschool age after fetal exposure to valproic acid and lamotrigine: cognitive, motor, sensory and behavioral function. Reprod Toxicol 41:115–125.
96. Robert E, Guibaud P. 1982. Maternal valproic acid and congenital neural tube defects. Lancet 2:937.
97. Rosa F. 2005. Lithium. In: Drugs in pregnancy and lactation. In: Briggs GG, Freeman RK, Yaffe SJ, editors. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. 7th ed. Philadelphia: Williams & Wilkins. pp. 929–934.
98. Rumeau-Rouquette C, Goujard J, Huel G. 1977. Possible teratogenic effect of phenothiazines in human beings. Teratology 15:57–64.
99. Schenker S, Yang Y, Mattiuz E, et al. 1999. Olanzapine transfer by human placenta. Clin Exp Pharmacol Physiol 26:691–697.
100. Schou M. 1976. What happened later to the lithium babies? A follow-up study of children born without malformations. Acta Psychiatr Scand 54:193–197.
101. Schrire I. 1963. Trifluoperazine and foetal abnormalities. Lancet 1:174.
102. Scolnik D, Nulman I, Rovet J, et al. 1994. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA 271:767–770.
103. Shallcross R, Bromley RL, Cheyne CP, et al. 2014. In utero exposure to levetiracetam vs valproate: development and language at 3 years of age. Neurology 82:213–221.
104. Shao P, Ou J, Peng M, et al. 2015. Effects of clozapine and other atypical antipsychotics on infants development who were exposed to as fetus: a post-hoc analysis. PLoS One 10:e0123373.
105. Shearer WT, Schreiner RL, Marshall RE. 1972. Urinary retention in a neonate secondary to maternal ingestion of nortriptyline. J Pediatr 81:570–572.
106. Simard M, Gumbiner B, Lee A, et al. 1989. Lithium carbonate intoxication. A case report and review of the literature. Arch Intern Med 149:36–46.
107. Sipek A. 1989. Lithium and Ebstein's anomaly. Cor Vasa 31:149–156.
108. Slone D, Siskind V, Heinonen OP, et al. 1977. Antenatal exposure to the phenothiazines in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score. Am J Obstet Gynecol 128:486–488.
109. Smit M, Dolman KM, Honig A. 2016. Mirtazapine in pregnancy and lactation - a systematic review. Eur Neuropsychopharmacol 26:126–135.
110. Stahl SM. 2003. Describing an atypical antipsychotic: receptor binding and its role in pathophysiology. J Clin Psychiatry 5(Suppl 3):5.
111. Tatsumi M, Groshan K, Blakely RD, Richelson E. 1997. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 340:249–258.
112. Thomas SV, Ajaykumar B, Sindhu K, et al. 2008. Cardiac malformations are increased in infants of mothers with epilepsy. Pediatr Cardiol 29:604–608.
113. Tomson T, Battino D, Bonizzoni E, et al. 2011. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 10:609–617.
114. Vajda FJ, Hitchcock A, Graham J, et al. 2006. Foetal malformations and seizure control: 52 months data of the Australian Pregnancy Registry. Eur J Neurol 13:645–654.
115. Vajda FJ, O'Brien TJ, Graham J, et al. 2016. Is carbamazepine a human teratogen? J Clin Neurosci 23:34–37.
116. Vajda FJ, O'Brien TJ, Lander CM, et al. 2014. The teratogenicity of the newer antiepileptic drugs - an update. Acta Neurol Scand 130:234–238.
117. van der Lugt NM, van de Maat JS, van Kamp IL, et al. 2012. Fetal, neonatal and developmental outcomes of lithium-exposed pregnancies. Early Hum Dev 88:375–378.
118. Vasilakis-Scaramozza C, Aschengrau A, Cabral H, Jick SS. 2013. Antidepressant use during early pregnancy and the risk of congenital anomalies. Pharmacotherapy 33:693–700.
119. Viguera AC, Cohen LS, Baldessarini RJ, Nonacs R. 2002. Managing bipolar disorder during pregnancy: weighing the risks and benefits. Can J Psychiatry 47:426–436.
120. Wakil L, Epperson CN, Gonzalez J, et al. 2009. Neonatal outcomes with the use of lamotrigine for bipolar disorder in pregnancy and breastfeeding: a case series and review of the literature. Psychopharmacol Bull 42:91–98.
121. Webster PA. 1973. Withdrawal symptoms in neonates associated with maternal antidepressant therapy. Lancet 2:318–319.
122. Weinbaum PJ, Cassidy SB, Vintzileos AM, et al. 1986. Prenatal detection of a neural tube defect after fetal exposure to valproic acid. Obstet Gynecol 67(Suppl):31S–33S.
123. Weinstein MR. 1976. The international register of lithium babies. Drug Inf J 10:94–100.
124. Werler MM, Ahrens KA, Bosco JL, et al. 2011. Use of antiepileptic medications in pregnancy in relation to risks of birth defects. Ann Epidemiol 21:842–850.
125. Weston J, Bromley R, Jackson CF, et al. 2016. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database Syst Rev 11:CD010224.
126. Wichman CL. 2009. Atypical antipsychotic use in pregnancy: a retrospective review. Arch Womens Ment Health 12:53–57.
127. Wide K, Henning E, Tomson T, Winbladh B. 2002. Psychomotor development in preschool children exposed to antiepileptic drugs in utero. Acta Paediatr 91:409–414.
128. Wilbanks GD, Bressler B, Peete CH Jr, et al. 1970. Toxic effects of lithium carbonate in a mother and newborn infant. JAMA 213:865–867.
129. Williams G, King J, Cunningham M, et al. 2001. Fetal valproate syndrome and autism: additional evidence of an association. Deve Med Child Neurol 43:202–206.
130. Winterfeld U, Klinger G, Panchaud A, et al. 2015. Pregnancy outcome following maternal exposure to mirtazapine: a multicenter, prospective study. J Clin Psychopharmacol 35:250–259.
131. Wu G, Nan C, Rollo JC, et al. 2010. Sodium valproate-induced congenital cardiac abnormalities in mice are associated with the inhibition of histone deacetylase. J Biomed Sci 17:16.
132. Yacobi S, Ornoy A. 2008. Is lithium a real teratogen? What can we conclude from the prospective versus retrospective studies? A review. Isr J Psychiatry Relat Sci 45:95–106.
133. Yonkers KA, Wisner KL, Stewart DE, et al. 2009. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry 31:403–413.
134. Zegers B, Andriessen P. 2003. Maternal lithium therapy and neonatal morbidity. Eur J Pediatr 162:348–349.